Skip to main content
STADA Arzneimittel AG logo

STADA Arzneimittel AG — Investor Relations & Filings

Ticker · SAZ ISIN · DE0007251803 LEI · 529900FMTTLMH0P0DL10 HM Manufacturing
Open in API
Filings indexed 916 across all filing types
Latest filing 2016-07-06 Board/Management Inform…
Country DE Germany
Listing HM SAZ

About STADA Arzneimittel AG

https://www.stada.com/

STADA Arzneimittel AG is a pharmaceutical company that operates on a three-pillar strategy consisting of generics, consumer healthcare products, and specialty pharmaceuticals. The company is a leading manufacturer of affordable generic medicines, which have been a core part of its business since its founding. In the consumer healthcare segment, STADA markets a wide portfolio of over-the-counter (OTC) products and well-known brands. The specialty pharmaceuticals division focuses on developing and marketing value-added medicines, including an expanding portfolio of biosimilars for therapeutic areas such as oncology, immunology, and bone health.

Recent filings

Filing Released Lang Actions
STADA Arzneimittel AG: Important step on the path to reconfiguring the STADA Supervisory Board
Board/Management Information Classification · 95% confidence The document is a press release announcing the candidates proposed for election to the Supervisory Board at the upcoming Annual General Meeting (AGM) on August 26, 2016. It details the selection process and the profiles of the proposed individuals. This content directly relates to the composition and governance structure of the board, which falls under Board/Management Information (MANG) or Governance Information (CGR). Since the core subject is the nomination and selection of board members, MANG is the most specific fit, as it covers 'Announcement of changes in the company's board of directors or senior management.' While it mentions the AGM, the primary focus is the management/board change, not the AGM materials themselves (AGM-R) or the voting results (DVA).
2016-07-06 English
DGAP-DD: STADA Arzneimittel AG english
Director's Dealing Classification · 100% confidence The document explicitly uses the header 'Directors’ Dealings' and details a transaction (Sale) involving a person subject to disclosure requirements (Luis Paul Retzlaff, dependent child of a Member of a managing body) in the shares of STADA Arzneimittel AG. This directly corresponds to the definition of Director's Dealing, which is classified under the code DIRS.
2016-06-30 English
DGAP-DD: STADA Arzneimittel AG english
Director's Dealing Classification · 100% confidence The document explicitly uses the header "Directors’ Dealings" and details a transaction (Sale of shares) by a person related to a member of the managing body (Dependent child of Eliza Marie Retzlaff). The text also references section 15a of the WpHG, which mandates such disclosures. This directly corresponds to the definition of Director's Dealing (Insider Trades). The filing type code is DIRS.
2016-06-30 English
Datum:30.06.2016
Annual Report Classification · 100% confidence The document is a comprehensive 'Geschäftsbericht 2015' (Annual Report 2015) for STADA Arzneimittel AG. It contains detailed financial statements, key performance indicators (KPIs), management's discussion and analysis (Vorwort des Vorstandsvorsitzenden), and the report of the supervisory board (Bericht des Aufsichtsrats). It covers the full fiscal year from 01.01.2015 to 31.12.2015. This fits the definition of a 10-K (Annual Report). FY 2015
2016-06-30 German
Datum:21.06.2016
Annual Report Classification · 100% confidence The document is a comprehensive annual financial statement ('Jahresabschluss') for STADA Arzneimittel AG for the fiscal year 2015. It includes a balance sheet ('Bilanz'), profit and loss statement ('Gewinn- und Verlustrechnung'), and detailed notes ('Anhang'). This constitutes a full annual report rather than a summary or announcement. In the context of German corporate filings, 'Jahresabschluss' is the standard term for the annual financial report, which maps to the 10-K category in the provided schema. FY 2015
2016-06-21 German
STADA Arzneimittel AG: Change in leadership at STADA
Board/Management Information Classification · 100% confidence The document is a press release announcing a significant change in the company's leadership, specifically the resignation of the Chief Executive Officer (CEO) and the appointment of a replacement. This directly corresponds to the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management.
2016-06-05 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.